Targeting the Microbiome: Therapeutic Approaches in Gastrointestinal Diseases
Friday, October 7, 2022
(7:45 AM CET – 4:35 PM CET)
Experience in-person presentations by our expert presenters and join interactive working sessions.
Event Overview
This full-day, educational event is organized for and by members of the ATRC to understand the role of the microbiome and microbiome therapeutics in GI diseases such as IBD and NASH. The Symposium will bring together key stakeholders including gastroenterologists, basic & translational scientists, clinical pharmacologists, trialists and industry sponsors.
Location: Courtyard by Marriott Vienna Prater/Messe
Address: Trabrennstraße 4 Wien, 1020 Österreich
Website: courtyard-wien-messe.com
Symposium: 7:45 AM CET – 4:35 PM CET; Krieau 1 and 2.
Reception: 4:35 AM CET- 6:35 PM CET; Foyer, Ground Floor.
| 7:45 AM CET | Registration & Continental Breakfast |
| 8:15 AM CET |
Welcome & Introductions Niels Vande Casteele — UCSD and AcelaBio, USA |
|
Session 1: Host-Microbe Interactions in Health and Gastrointestinal Diseases Chair: Niels Vande Casteele - UCSD and AcelaBio, USA |
|
| 8:30 AM |
Keynote: Host-Microbe Interactions in Health and Gastrointestinal Diseases Eugene Chang — University of Chicago, USA |
| 9:10 AM |
Keynote: Microbiome-Based Precision Medicine Purna Kashyap — Mayo Clinic, USA |
| 9:50 AM | Panel Discussion |
| 10:05 AM | Break |
|
Session 2: Modulating Microbial Pathways as a Theraputic Intervention Chair: João Sabino - KU Leuven, Belgium |
|
| 10:20 AM |
Microbiota Guided Assessment of Therapy Response to Biologicals in IBD Wouter de Jonge — Amsterdam UMC, The Netherlands |
| 10:40 AM |
The Evolution of the use of Faecal Microbiota Transplantation and Emerging Therapeutic Indications Jessica Allegretti — Harvard Medical School, USA |
| 11:00 AM |
Leveraging Interventional Studies to Drive Novel Microbiome Therapeutic Development Christopher Ford — SERES Therapeutics, USA |
| 11:20 AM |
Bacteriophages and Their Potential for Treatment of Gastrointestinal Diseases Bernd Schnabl — University of California San Diego, USA |
| 11:40 AM |
Bench to Trial: Microbial-Immune Modulation in IBD with Defined Bacterial Consortia Amanda Prince — Vedanta Biosciences, USA |
| 12:00 PM | Panel Discussion |
| 12:30 PM | Lunch |
|
Session 3: Microbiome Clinical Trial Design Chair: Vipul Jairath - UWO and Alimentiv, Canada |
|
| 1:30 PM |
Challenges in the Design and Conduct of Clinical Trials in Mild to Moderate Ulcerative Colitis Vipul Jairath — University of Western Ontario and Alimentiv, Canada |
| 1:55 PM |
Considerations for Targeting the Microbiome in Clinical Development Harry Sokol — Sorbonne University and APHP, France |
| 2:20 PM | Panel discussion |
| 2:40 PM | Break |
|
Session 4: Breakout Session Chair: Niels Vande Casteele - UCSD and AcelaBio, USA |
|
| 2:55 PM | Instructions for Breakout Groups |
| 3:00 PM | Working groups to identify gaps and practicalities of implementation of microbiome studies in clinical trials |
| 3:40 PM | Working group presentation & general discussion |
| 4:25 PM | Summary of proposed objectives |
| 4:35 PM | Adjourn & Reception |
